| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d5de9a1dac6b033c4643bb236ef4df3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-11023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-14023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-12023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16022 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-08 |
| filingDate |
2018-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8317107bbc4f3f2e90d69f988e01e6ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14fba97f5e5e34e1c05d52e6752366d3 |
| publicationDate |
2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018183435-A1 |
| titleOfInvention |
Vlp-based bivalent ebola vaccines and methods of making and using same |
| abstract |
Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group- specific Antigen ("Gag") protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein. |
| priorityDate |
2017-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |